CAS: 303-42-4; Methenolone Enanthate

该化合物是一种源自二氢苯丙酮(DHT)的代谢类类类固醇,其特点是长效酯,可持续释放并产生长期影响.甲基苯丙酮以其代谢特性著称,促进肌肉成长和体力,同时表现出相对低的和诱导性活性.这使得运动员和体力制造者中的一种流行选择,即试图以较弱的副作用提高性能,通常与较强的代谢类固醇有关.该化合物通常通过体内注射来施用,并有利于其在不大量保留水的情况下促进精性肌肉质量.此外,甲基苯丙酸酯具有有利的安全性特征,其肝毒性风险低于口服代谢类固醇.然而,与所有代谢剂一样,它在许多国家受到法律限制,应在医疗监督下谨慎地加以利用,以减轻潜在不利影响.

英文名称Methenolone Enanthate
中文名称美替诺龙庚酸酯
IUPAC名称[(5S,8R,9S,10S,13S,14S,17S)-1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] heptanoate
其它别名[(5S,8R,9S,10S,13S,14S,17S)-1,10,13-Trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydr°Cyclopenta[a]phenanthren-17-yl] heptanoate
CAS编号303-42-4
MFCD编号:MFCD00864190
EINECS号:206-141-6
FDA UNII编号:0SPD480WFH
分子式:C27H42O3
分子量:414.62
产品CID: 1288062
产品分类医药中间体 → 原料药中间体

相似结构搜索
InChIKey: TXUICONDJPYNPY-FRXWOFFRSA-N
TXUICONDJPYNPY-AGMOSJHJNA-N…
计算化学: 氢键受体数3.0氢键供体数0.0可旋转键数7.0

物理性质

熔点289-292 °C
沸点504.3±50.0 °C at 760 mmHg
闪点213.1±30.2 °C
密度1.1±0.1 g/cm3
PSA:43.37
LogP:7.58
折射率1.526
蒸汽压0.0±1.3 mmHg at 25°C
溶解性DMF: 30 mg/mL; DMSO: 11 mg/mL; Ethanol: 25 mg/mL
外观形态结晶性固体
储存条件2~8°C

MSDS等安全信息

GHS符号GHS07,GHS08
警示词Danger
危险描述H302-H360-H362-H351
防范说明P201-P260-P263-P264-P270-P308+P313-P201-P202-P281-P308+P313-P405-P501-P264-P270-P301+P312-P330-P501
危险品标志Xi
安全声明S22-S26-S36/37/39
危险类别码R22

合成工艺路线路线简述

海关参考信息

2901210000-乙烯
2901220000-丙烯
2905122000-异丙醇
2909110000-乙醚
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:US-2025281509-A1
优先权日:2021-04-26
标题 :Sequential hormone therapy to improve survival and enhance response to immune therapy in men with prostate cancer
发明人：DENMEADE SAMUEL R; ISAACS JOHN T; ANTONARAKIS EMMANUEL S; KACHHAP SUSHANT; MARKOWSKI MARK CHRISTOPHER
权利人:UNIV JOHNS HOPKINS
摘要:Disclosed are methods for treating men with castrate resistant prostate cancer with a sufficient dose of testosterone to achieve supraphysiologic serum levels of testosterone in sequence with androgen ablative treatment or androgen synthesis inhibitors for one or more cycles until evidence of radiographic progression, at which point the subject will receive immune checkpoint blockade therapy.